Literature DB >> 19817895

Breast cancer in the elderly: a histological assessment.

Gary M Tse1, Puay-Hoon Tan, Kin-Mang Lau, Victor Piana de Andrade, Philip C W Lui, Joaquim S Vong, Benjaporn Chaiwun, Christopher C Lam, Alex M Yu, Takuya Moriya.   

Abstract

AIMS: To understand the correlation between the expression status of different biological markers in breast cancers in the elderly. METHODS AND
RESULTS: Three hundred and ninety-seven cases were evaluated for expression of hormone receptors [oestrogen receptors (ER) alpha and beta, progesterone receptor (PR)], basal markers [p63, cytokeratin (CK) 5/6 and CK14] and others (HER2/neu, synaptophysin and chromogranin). The expression rates were 60, 29, 25, 6, 14, 8, 28, 17 and 5%, respectively, for these markers. The expression of ER alpha and beta, PR, synaptophysin and chromogranin at any level correlated with low nuclear or tumour grades, whereas the expression of HER2/neu, CK5/6 and CK14 at any level correlated with high nuclear grade. By using hierarchical clustering, groups of HER2, luminal and basal types were identified. In addition, a neuroendocrine group was also identified, being characterized by expression of synaptophysin, chromogranin, ER and PR, but not HER2/neu, and other basal cytokeratins. This group was associated with lower nuclear grade, and hence better prognosis.
CONCLUSIONS: Breast cancer in the elderly shows similar molecular groupings as other breast cancers, with an additional neuroendocrine group that is associated with a favourable biological marker profile.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19817895     DOI: 10.1111/j.1365-2559.2009.03400.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Current targeted therapies in breast cancer: clinical applications in the elderly woman.

Authors:  Jean-Philippe Spano; Claire Falandry; Pascal Chaibi; Gilles Freyer
Journal:  Oncologist       Date:  2011-06-24

Review 2.  Primary neuroendocrine breast cancer, how much do we know so far?

Authors:  Homam Alkaied; Kassem Harris; Basem Azab; Qun Dai
Journal:  Med Oncol       Date:  2012-04-01       Impact factor: 3.064

3.  Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts.

Authors:  B M Syed; A R Green; E C Paish; D Soria; J Garibaldi; L Morgan; D A L Morgan; I O Ellis; K L Cheung
Journal:  Br J Cancer       Date:  2013-03-05       Impact factor: 7.640

Review 4.  [Neuroendocrine carcinoma of the breast: about a case and review of the literature].

Authors:  Hinde El Fatemi; Nawal Hammas; Kaoutar Moumna; Mouhcine Bedahou; Nawfel Mellas; Omar Mesbahi
Journal:  Pan Afr Med J       Date:  2012-10-29

Review 5.  How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.

Authors:  Diana P Saraiva; M Guadalupe Cabral; António Jacinto; Sofia Braga
Journal:  ESMO Open       Date:  2017-09-14

6.  Primary neuroendocrine tumors of the breast: two case reports and review of the literature.

Authors:  Loubna Hejjane; Karima Oualla; Zineb Bouchbika; Mouna Bourhafour; Anas Lhlou Mimi; Efared Boubacar; Abdellatif Benider; Zineb Benbrahim; Samia Aarifi; Nawef Mellas
Journal:  J Med Case Rep       Date:  2020-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.